Please login to the form below

Not currently logged in
Email:
Password:

Horizon Pharma

This page shows the latest Horizon Pharma news and features for those working in and with pharma, biotech and healthcare.

Horizon Discovery and C4X to harness CRISPR for new cancer drugs

Horizon Discovery and C4X to harness CRISPR for new cancer drugs

Cambridge-based Horizon has its own proprietary gene editing and gene modulation technologies. ... Horizon and C4X say pharma companies are now using traditional empirical research to identify other compounds which can produce this effect – but claim

Latest news

  • CHMP backs Sanofi’s all-oral sleeping sickness drug CHMP backs Sanofi’s all-oral sleeping sickness drug

    Vertex Pharma got the okay to extend the use of its Orkambi (lumacaftor/ivacaftor) cystic fibrosis drug to include patients aged 2 to 5 years old who have two copies of ... the F508del mutation, while Horizon Pharma’s Ravicti (glycerol phenylbutyrate)

  • UK pharma cheers EU science announcement UK pharma cheers EU science announcement

    UK won't be excluded from Horizon research collaboration. Amid all the chaos and confusion of Brexit, the UK pharma industry finally has some good news to latch onto – it ... Meanwhile along with welcoming the Horizon Europe development, Porkess also re

  • What’s on the horizon? What’s on the horizon?

    The evolving role of the healthcare expert.

  • Horizon swoops on Raptor to add rare disease products Horizon swoops on Raptor to add rare disease products

    Gains two new orphan medicines through the $800m deal.  . Ireland's Horizon Pharma has bolstered its position in orphan diseases with an $800m agreement to buy Raptor Pharmaceutical of the US. ... Horizon sales are predicted to be around $1bn this year,

  • Allergan CEO takes issue with 'predatory' price increases Allergan CEO takes issue with 'predatory' price increases

    Allergan chief executive Brent Saunders has slammed aggressive price increases in the pharma sector, saying they break an "unwritten social contract". ... Meanwhile other companies - including Valeant, Turing Pharma and Horizon Pharma - have also been

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... Upfront $80m plus $830m in milestones [ex S. Korea]. 910. Raptor / Horizon Pharma.

  • Deal Watch October 2015 Deal Watch October 2015

    This was exemplified by the major asset swapping amongst pharma companies of last year. ... More big pharma acquisitions on the horizon? We cannot close this month's Deal Watch without mentioning the reports filtering out near the end of October that

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    For an indepth analysis of these deals, read'Pharma deals during March 2014'. ... Vidara Therapeutics/. Horizon Pharma. Merger/ acquisition. Actimmune (interferon gamma-1b) for CGD and SMO (approved).

  • Pharma deals during March 2014 Pharma deals during March 2014

    US-based Horizon Pharma's acquisition of Irish-based Vidara Therapeutics via a reverse merger for cash and stock comes in at $660m. ... The NewCo will be called Horizon Pharma plc and will be an Irish company to take advantage of the lower corporate tax

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Ziarco appoints Mike Grey to board of directors Ziarco appoints Mike Grey to board of directors

    Grey has served as CEO at numerous biopharma companies, including Auspex Pharma, SGZ Pharma and Trega Biosciences. ... Grey is currently on the boards of BioMarin Pharma, Horizon Pharma, Mirati Therapeutics and Selventa.

  • Horizon Discovery appoints executive director Horizon Discovery appoints executive director

    Smoller joined Horizon as chief business officer as part of the form's acquisition of Sage Labs for $48m in September this year. ... 1996. Horizon is a UK-based biotech focused on genomics research and the development of personalised medicines.

  • Horizon adds AZ’s Galbraith to board Horizon adds AZ’s Galbraith to board

    Galbraith is senior VP and head of oncology innovative medicines at AZ and knows Horizon well thanks to a collaboration between the two companies on personalised cancer treatments. ... We believe each will be an invaluable asset to Horizon, and look

  • Horizon appoints board chair Horizon appoints board chair

    Dr Gilham's prior experience also includes senior positions at leading pharma companies, such as GlaxoSmithKline and Abbott Labs. ... from his guidance as Horizon continues to develop as a world-leading translational genomics organisation.".

  • Oscar Ferenczi joins Grünenthal from Sandoz Oscar Ferenczi joins Grünenthal from Sandoz

    Will lead German pharma company's Latin American expansion plans. Grünenthal has appointed former region head of Sandoz Latin America Oscar Ferenczi to lead its own Latin America business. ... and an agreement with US-based Horizon Pharma for the

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics